Here are six key points:
1. The Good Laboratory Practice protocol testing involved a 12-porcine subject clinical analysis of the DenerveX System at zero days, 30 days and 60 days post procedure.
2. The study included 144 treatments, with 48 treatment sites initially evaluated.
3. Of those 48 treatment sites, 92 percent of the DenerveX System treatments reached the targeted facet joint treatment sites.
4. The researchers found no signs of neurodegeneration at the dorsal nerve roots and dorsal ganglia.
5. The DenerveX System includes the DenerveX device and DenerveX Pro-40 Power Generator, intended to be less invasive.
6. The system has not received a CE mark or FDA clearance, yet.
More articles on devices:
Surgeon-driven innovation in spine surgery: TranS1 CEO on 2 new innovations & what the future holds
CareCloud to integrate population health management tools into Lightbeam’s clinical platform: 3 notes
Surgeons complete 1.5k surgeries using Zimmer Biomet’s Vitality System — 5 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
